These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 19430296)

  • 1. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD; Jones MA; Beadle GF; Stein SR
    Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.
    Papouchado BG; Myles J; Lloyd RV; Stoler M; Oliveira AM; Downs-Kelly E; Morey A; Bilous M; Nagle R; Prescott N; Wang L; Dragovich L; McElhinny A; Garcia CF; Ranger-Moore J; Free H; Powell W; Loftus M; Pettay J; Gaire F; Roberts C; Dietel M; Roche P; Grogan T; Tubbs R
    Am J Surg Pathol; 2010 Jun; 34(6):767-76. PubMed ID: 20421783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
    Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
    Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer.
    Pedersen M; Rasmussen BB
    Diagn Mol Pathol; 2009 Jun; 18(2):96-102. PubMed ID: 19430295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).
    Kato N; Itoh H; Serizawa A; Hatanaka Y; Umemura S; Osamura RY
    Pathol Int; 2010 Jul; 60(7):510-5. PubMed ID: 20594272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.
    Shousha S; Peston D; Amo-Takyi B; Morgan M; Jasani B
    Histopathology; 2009 Jan; 54(2):248-53. PubMed ID: 19207950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification.
    Moelans CB; de Weger RA; van Diest PJ
    Breast Cancer Res Treat; 2010 Feb; 120(1):1-7. PubMed ID: 19760503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
    Bilous M; Morey A; Armes J; Cummings M; Francis G
    Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer.
    Di Palma S; Collins N; Bilous M; Sapino A; Mottolese M; Kapranos N; Schmitt F; Isola J
    J Clin Pathol; 2008 Jun; 61(6):757-60. PubMed ID: 18326010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of silver-enhanced in situ hybridization for evaluating HER2 gene status in invasive breast carcinoma: a comparative study.
    Lee Y; Ryu Y; Jeong H; Chang H; Kim Y; Kim A
    Arch Med Res; 2012 Feb; 43(2):139-44. PubMed ID: 22475781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours.
    Laakso M; Tanner M; Isola J
    J Pathol; 2006 Sep; 210(1):3-9. PubMed ID: 16823892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
    Lim SJ; Cantillep A; Carpenter PM
    Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer.
    Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
    Exp Mol Pathol; 2007 Jun; 82(3):262-8. PubMed ID: 17335803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
    Akhdar A; Bronsard M; Lemieux R; Geha S
    Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of reliability of FISH versus brightfield dual-probe in situ hybridization (BDISH) for frontline assessment of HER2 status in breast cancer samples in a community setting: influence of poor tissue preservation.
    Schiavon BN; Jasani B; de Brot L; Vassallo J; Damascena A; Cirullo-Neto J; Ivanildo Neves J; Augusto Soares F; Gobbi H; Malagoli Rocha R
    Am J Surg Pathol; 2012 Oct; 36(10):1489-96. PubMed ID: 22982892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria.
    Gong Y; Sweet W; Duh YJ; Greenfield L; Tarco E; Trivedi S; Symmans WF; Isola J; Sneige N
    Am J Clin Pathol; 2009 Aug; 132(2):228-36. PubMed ID: 19605817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH).
    Fritzsche FR; Bode PK; Moch H; Kristiansen G; Varga Z; Bode B
    Am J Surg Pathol; 2010 Aug; 34(8):1180-5. PubMed ID: 20661016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
    Bhargava R; Lal P; Chen B
    Am J Clin Pathol; 2005 Feb; 123(2):237-43. PubMed ID: 15842048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
    Dandachi N; Dietze O; Hauser-Kronberger C
    Anticancer Res; 2004; 24(4):2401-6. PubMed ID: 15330190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry.
    Kounelis S; Kapranos N; Malamos N; Kouri-Bairaktari E
    Anticancer Res; 2005; 25(2A):939-46. PubMed ID: 15868931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.